RecruitingNot ApplicableNCT06669533

Use Misoprostol to Optimize Prevention of Cervical Cancer

Misoprostol to Optimizing Prevention of Cancer of the Cervix: A Double-Blind Randomized Controlled Trial


Sponsor

University of Alabama at Birmingham

Enrollment

420 participants

Start Date

Feb 25, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This is a double-blind randomized controlled trial of 420 non-pregnant women undergoing cancer screening by visual inspection with acetic acid (VIA) who have Type 3 transformation zone (TZ) and randomized to receive either Misoprostol or placebo.


Eligibility

Sex: FEMALEMin Age: 25 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether using misoprostol (a medication that softens the cervix) can improve the success of a cervical cancer prevention procedure called LEEP or cold knife conization. These procedures remove pre-cancerous cells from the cervix, and the study focuses on women with a specific cervical anatomy (Type 3 transformation zone) that makes the procedure more difficult. **You may be eligible if...** - You are 25 or older - You have a Type 3 transformation zone confirmed by exam (meaning the cervix's cell-change zone extends inside the cervical canal, making it harder to assess) **You may NOT be eligible if...** - You have a Type 1 or Type 2 transformation zone - You are pregnant - You have had a hysterectomy - You have a cancerous lesion - You have active cervical infection Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPlacebo

Participants will receive placebo (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).

DRUGMisoprostol

Participants will receive 600 mcg misoprostol (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).


Locations(1)

Cameroon Baptist Convention Health Core, EtougEbe Baptist Hospital Yaoundé

Yaoundé, Center Region, Cameroon

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06669533


Related Trials